We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cyclenium, Fundación MEDINA Drug Discovery Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cyclenium, Fundación MEDINA Drug Discovery Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cyclenium Pharma Inc. and Fundación MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía) have announced the signing of a drug discovery and collaboration agreement.

The collaboration will utilize Cyclenium’s proprietary QUEST Library™ of next generation macrocyclic molecules and associated hit-to-clinical candidate optimization capabilities in concert with the extensive expertise and experience of Fundación MEDINA in infective disease research.

The objective of the collaboration is to discover new anti-infective drug candidates effective against a number of clinically important bacterial and fungal pathogens. For Cyclenium, this is the fourth discovery collaboration established over the past year.

“We are extremely excited about entering into this unique drug discovery collaboration with the Fundación MEDINA in one of our therapeutic focus areas,” stated Helmut Thomas, Ph.D., President & Chief Executive Officer of Cyclenium.

Thomas continued, “The combination of their superb team and world class expertise in anti-infective research with our CMRT™ Technology and proven development success in the macrocycle arena offers an excellent opportunity for discovering desperately needed novel pharmaceutical agents against high priority, treatment resistant, bacterial and fungal organisms.”

“This relationship represents a strategic collaboration to identify novel drugs in the area of infectious diseases from the exploitation of Cyclenium’s unique library complementing the chemical diversity of our natural product libraries,” said Olga Genilloud, Ph.D., Scientific Director, Fundación MEDINA. “MEDINA provides the expertise and tools to maximize the probability of success in the collaboration with Cyclenium and the discovery of promising compounds for the treatment of serious multidrug resistant infections.”